ARS targets breakeven after H2 2026 cost cuts

ARS Pharmaceuticals (SPRY) said it is aiming to reach cash-flow breakeven by December 31, 2027, and outlined a cost-reduction plan tied to its commercial priorities. On the company’s Q2 2026 earnings call, officials said ARS has lowered its expected cash-based spending to support that while continuing the rollout of its product, Neffy.

Officials said the company now expects cash-based SG&A and R&D in H2 2026 to come in at $100 million–$110 million. They described the reductions as a way to narrow operating losses while maintaining support for Neffy’s commercial launch activities.

H2 2026 guidance focuses on cash spending Officials H2 2026 guidance focuses on cash spending Officials emphasized that the $100 million–$110 million range Officials emphasized that the $100 million–$110 million range covers only cash-based SG&A and R&D, and does not include non-cash items. The company said the revised guidance is designed to reduce H2 cash burn and extend its operating runway toward the breakeven target. In the same update, the company said the intent is to make progress without depending on additional financing. Officials framed the approach as aligning spending levels with operational needs as ARS continues executing its plan around Neffy. Neffy rollout and supply update The company said Neffy gained market share during the quarter. Officials linked the cost plan to keeping the commercial rollout supported while tightening overall expenditure levels. Officials also provided an update related to clinical supply (CSU), the company said, without detailing further in the information provided. The supply situation was presented as part of the operational factors being monitored alongside commercial progress.

Financing sensitivity tied to sales and run-rate

Officials said that if the H2 cost run-rate holds and Neffy sales continue to grow, the plan is intended to reduce reliance on near-term equity raises. The company said this could lessen expected dilution pressure, which can be a key concern for shareholders when external funding becomes necessary. ARS Pharmaceuticals At the same time, officials warned that outcomes depend on execution. They said that if sales weaken or if supply constraints persist, additional cost actions or external financing could be required, which would weigh on shareholders.

Market reaction was not yet available at the time of the update. ARS reiterated, through officials’ comments, that its stated objective remains cash-flow breakeven by December 31, 2027.